Breaking News Instant updates and real-time market news.

NVTR

Nuvectra

$15.35

-0.05 (-0.32%)

16:05
08/07/18
08/07
16:05
08/07/18
16:05

Nuvectra reports Q2 EPS (83c), consensus (91c)

Reports Q2 revenue $13.1M, consensus $11.68M. Scott Drees, CEO, said, "The second quarter represented another record quarter for our Algovita business, which benefited from new accounts, as well as from increased penetration in existing accounts. Our growth was further accelerated through the continued expansion of our U.S. commercial team, which now approximates 60 active territories. We look forward to further advancing our commercial momentum through 2018 and beginning to prepare for 2019." Mr. Drees continued, "With respect to Virtis, we have recently filed our response to FDA's requests, which we received late in the second quarter. FDA now has 180 days from our submission to review our response. Our focus remains on gaining U.S. approval as soon as possible, and we are working proactively with FDA to this end."

  • 07

    Aug

NVTR Nuvectra
$15.35

-0.05 (-0.32%)

06/21/18
RHCO
06/21/18
NO CHANGE
Target $27
RHCO
Buy
Nuvectra price target raised to $27 from $19 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Nuvectra to $27 and kept his Buy rating, citing his expectations of continued momentum in the spinal cord stimulation market. The analyst sees the sales force augmentation, MRI label, and a growing body of clinical evidence starting in 2019, along with its entry into the $600M sacral nerve modulation market this year, as the drivers of performance. Nudell says his new price target is also derived by modeling a 5.2-times enterprise value to sales ratio to his expected FY22 revenues - a multiple that is generally in-line with recent small-cap med-tech acquisitions - and discounting it to the present.
07/02/18
PIPR
07/02/18
NO CHANGE
Target $16
PIPR
Overweight
Piper says Nuvectra disappointing but not disastrous delay a buying opportunity
After Nuvectra reported that the FDA has requested that the company provide additional information related to any Virtis modifications as well as further MRI data and that European regulators requested clinical data before granting approval, Piper Jaffray analyst Matt O'Brien called the delays "surprising and disappointing," but not "catastrophic" or "disastrous." The FDA issues should be able to be overcome, while the EU delay looks "more onerous," but O'Brien thinks the market foreign market is not nearly as important from the domestic one, he tells investors. The analyst, who recommends purchasing Nuvectra shares amid the pullback created by the delay, keeps an Overweight rating on the stock with a $16 price target.
07/03/18
JMPS
07/03/18
NO CHANGE
Target $18
JMPS
Outperform
JMP Securities remains a buyers of Nuvectra after regulatory update
JMP Securities analyst David Turkaly noted that Nuvectra shares closed down 15% yesterday following the company's regulatory updates, but he remains a buyer of the stock as he still believes FDA approval for Virtis remains intact for the second half of 2018. The new questions from the FDA appear "relatively benign" and having the pre-PMA audit completed with no observations is a positive event, Turkaly tells investors. He maintains an Outperform rating and $18 price target on Nuvectra shares.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $18
PIPR
Overweight
Piper calls Nuvectra a favorite microcap name, ups target to $18
Piper Jaffray analyst Matt O'Brien calls Nuvectra one of his firm's favorite microcap names and upped his price target for the shares to $18 from $16. The Centers for Medicare and Medicaid Services last Friday released the 2019 proposed SCS reimbursement rates for physician professional services, which increased 19% from the 2018 final rates for both the implantation of first and second trial leads, O'Brien tells investors in a research note. The reimbursement rate increase "should shift the paradigm toward SCS procedures over opioid prescriptions over time," according to the company, the analyst adds. He views the proposed rates as a potential catalyst for Nuvectra and keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

NYT

New York Times

$26.07

-0.275 (-1.04%)

15:40
11/13/18
11/13
15:40
11/13/18
15:40
Periodicals
New York Times 'stands by' North Korea story criticized by President Trump »

NYTimes Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBBN

Ribbon Communications

$5.04

-1.6 (-24.10%)

15:37
11/13/18
11/13
15:37
11/13/18
15:37
Hot Stocks
Breaking Hot Stocks news story on Ribbon Communications »

Ribbon Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SA

Seabridge Gold

$11.74

-0.21 (-1.76%)

15:34
11/13/18
11/13
15:34
11/13/18
15:34
Options
Seabridge Gold options imply 5.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBBN

Ribbon Communications

$4.98

-1.66 (-25.00%)

15:32
11/13/18
11/13
15:32
11/13/18
15:32
Hot Stocks
Breaking Hot Stocks news story on Ribbon Communications »

Ribbon Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$132.00

0.49 (0.37%)

, AAPL

Apple

$193.20

-0.955 (-0.49%)

15:27
11/13/18
11/13
15:27
11/13/18
15:27
Periodicals
Spotify launches Apple Watch app, missing major features, Gizmodo says »

After months of rumors…

SPOT

Spotify

$132.00

0.49 (0.37%)

AAPL

Apple

$193.20

-0.955 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

BL

BlackLine

$40.64

-0.01 (-0.02%)

15:25
11/13/18
11/13
15:25
11/13/18
15:25
Conference/Events
BlackLine to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NEPT

Neptune Wellness

$3.31

-0.03 (-0.90%)

15:19
11/13/18
11/13
15:19
11/13/18
15:19
Options
Neptune Technologies options imply 19.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/13/18
11/13
15:17
11/13/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$15.73

-4.1 (-20.68%)

15:16
11/13/18
11/13
15:16
11/13/18
15:16
Recommendations
Amarin analyst commentary  »

Physicians not concerned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/13/18
11/13
15:16
11/13/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$179.85

0.34 (0.19%)

15:16
11/13/18
11/13
15:16
11/13/18
15:16
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

FB

Facebook

$142.51

0.99 (0.70%)

15:11
11/13/18
11/13
15:11
11/13/18
15:11
Hot Stocks
Facebook took down 141 accounts following FBI tip »

Facebook said that last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

THC

Tenet

$23.33

-2.39 (-9.29%)

15:10
11/13/18
11/13
15:10
11/13/18
15:10
Options
$2M call buy in Tenet Healthcare as shares lose 9% »

$2M call buy in Tenet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

15:10
11/13/18
11/13
15:10
11/13/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

AMC

AMC Entertainment

$15.49

0.3 (1.98%)

15:08
11/13/18
11/13
15:08
11/13/18
15:08
Recommendations
AMC Entertainment analyst commentary  »

AMC seeing success with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 04

    Dec

AAWW

Atlas Air

$55.19

2.03 (3.82%)

15:05
11/13/18
11/13
15:05
11/13/18
15:05
Hot Stocks
Atlas Air, Southern Air announce pathway program agreement with Ameriflight »

Atlas Air Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIX

Wix.com

$90.46

1.99 (2.25%)

15:04
11/13/18
11/13
15:04
11/13/18
15:04
Options
Wix.com options imply 18.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

ECA

Encana

$8.10

-0.31 (-3.69%)

15:00
11/13/18
11/13
15:00
11/13/18
15:00
Options
Encana option volume hits year high as shares touch year lows »

Encana option volume hits…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QRVO

Qorvo

$63.45

-0.35 (-0.55%)

, AAPL

Apple

$193.43

-0.725 (-0.37%)

14:51
11/13/18
11/13
14:51
11/13/18
14:51
Recommendations
Qorvo, Apple, Lumentum, Skyworks, Cirrus Logic, Broadcom analyst commentary  »

After Qorvo warns, MKM…

QRVO

Qorvo

$63.45

-0.35 (-0.55%)

AAPL

Apple

$193.43

-0.725 (-0.37%)

LITE

Lumentum

$38.92

1.415 (3.77%)

SWKS

Skyworks

$72.16

-0.61 (-0.84%)

CRUS

Cirrus Logic

$37.63

1.99 (5.58%)

AVGO

Broadcom

$224.39

0.84 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 06

    Dec

QRVO

Qorvo

$63.36

-0.44 (-0.69%)

, AAPL

Apple

$193.50

-0.655 (-0.34%)

14:51
11/13/18
11/13
14:51
11/13/18
14:51
Recommendations
Qorvo, Apple analyst commentary  »

JPMorgan sees…

QRVO

Qorvo

$63.36

-0.44 (-0.69%)

AAPL

Apple

$193.50

-0.655 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

AMRS

Amyris

$6.05

0.19 (3.24%)

14:49
11/13/18
11/13
14:49
11/13/18
14:49
Options
Amyris options imply 19.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BA

Boeing

$347.91

-9.02 (-2.53%)

14:46
11/13/18
11/13
14:46
11/13/18
14:46
Periodicals
Pilots claim Boeing Lion Air crash linked to improper training, FT reports »

Pilot associations said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$193.31

-0.845 (-0.44%)

14:45
11/13/18
11/13
14:45
11/13/18
14:45
Technical Analysis
Technical Take: Apple moves lower after rally fails »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

XLK

Technology Select Sector SPDR

$67.49

0.08 (0.12%)

14:40
11/13/18
11/13
14:40
11/13/18
14:40
Options
Aggressive call buying in SPDR Tech Fund »

Aggressive call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QRVO

Qorvo

, AAPL

Apple

$192.80

-1.355 (-0.70%)

14:37
11/13/18
11/13
14:37
11/13/18
14:37
Recommendations
Qorvo, Apple analyst commentary  »

Qorvo price target…

QRVO

Qorvo

AAPL

Apple

$192.80

-1.355 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.